HomeIndustriesHealthcareSpyre (SYRE) CEO On IBD Market Growth

Spyre (SYRE) CEO On IBD Market Growth

Spyre (SYRE) is a biotech company that aims to create the next-generation of inflammatory bowel disease products. CEO Cameron Tuttle joins Oliver Renick to discuss the company as it began trading on the NASDAQ following an acquisition of Aeglea. Tuttle talks about how the IBD market is expected to grow to $29B by 2028, as the CDC estimates that 3.1M Americans have been diagnosed with IBD. Tune in to find out more about the stock market today.

Morning Trade Live

06 Dec 2023

SHARE

ON AIR
3:00 am
Fast Market
replay
12:00 am
Market Overtime
REPLAY
12:30 am
Market On Close
REPLAY
education
2:00 am
Your First Trade
REPLAY
education
2:30 am
Your First Trade
REPLAY
ON AIR
3:00 am
Fast Market
REPLAY
4:00 am
Next Gen Investing
REPLAY
5:00 am
Market Overtime
REPLAY
5:30 am
The Wrap
REPLAY
7:00 am
Morning Movers
8:00 am
Opening Bell With Nicole Petallides
9:00 am
Morning Trade Live
10:00 am
Trading 360
11:00 am
Fast Market
12:00 pm
Next Gen Investing
1:00 pm
The Watch List
2:00 pm
Market On Close
3:30 pm
Market Overtime
REPLAY
4:00 pm
Fast Market
REPLAY
5:00 pm
Next Gen Investing
REPLAY
6:00 pm
The Wrap
REPLAY
education
7:30 pm
Liz Ann Live
REPLAY
8:00 pm
Market Overtime
REPLAY
8:30 pm
Market On Close
REPLAY
education
10:00 pm
Liz Ann Live
REPLAY
10:30 pm
The Wrap
REPLAY

Schwab Network's Newsletters

Daily insights for every investor